X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The published results include data from tumor cell lines and experimental tumor models and support the high therapeutic potential of INT-1B3 in solid tumor indications.
Lead Product(s): INT-1B3
Therapeutic Area: Oncology Product Name: INT-1B3
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2021
Details:
The award will support the clinical validation of the Company’s lead candidate, microRNA candidate INT-1B3, for the treatment of solid tumors.
Lead Product(s): INT-1B3
Therapeutic Area: Oncology Product Name: INT-1B3
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dutch Government
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Funding March 11, 2021
Details:
INT-1B3 is a microRNA-mimic of the endogenous tumour suppressor miR-193a-3p formulated in next-generation lipid nanoparticles and can potentially address various hallmarks of cancer at the same time.
Lead Product(s): INT-1B3
Therapeutic Area: Oncology Product Name: INT-1B3
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
First-in-human trial will test the safety, pharmacokinetics and preliminary efficacy of microRNA therapeutic candidate INT-1B3.
Lead Product(s): INT-1B3
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
